BerGenBio ASA
OTC: BRRGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Oystein Soug
- Employees
- 13
- Headquarters
- Bergen, Norway
- IPO year
- 2018
- Market cap
- $9.5B
- Website
- https://www.bergenbio.com
Loading BRRGF…
Loading profile data…Frequently asked questions about BRRGF
What does BerGenBio ASA (BRRGF) do?
BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor...
Where does BRRGF trade?
BerGenBio ASA (BRRGF) trades on the Other OTC.
What sector is BRRGF in?
BerGenBio ASA (BRRGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BerGenBio ASA?
Oystein Soug is the chief executive officer of BerGenBio ASA (BRRGF).
Where is BerGenBio ASA headquartered?
BerGenBio ASA is headquartered in Norway.
Does BRRGF pay a dividend?
BerGenBio ASA (BRRGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BRRGF go public?
BerGenBio ASA (BRRGF) completed its initial public offering in 2018.